IKI. F. Kustova

I. F. Kustova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. F. Kustova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples

    by L. M. Dyakov, O. M. Krivtsova, P. A. Khesina, I. F. Kustova, N. A. Dyakova, N. S. Muge, N. E. Kudashkin, Yu. I. Patyutko, N. L. Lazarevich, Ю. И. Патютко

    Introduction. Liquid biopsy is considered as a minimally invasive method of molecular genetic analysis that can be used for early diagnosis, prognosis of disease development, monitoring of residual disease or treatment outcomes, and selection of optimal drug therapy schemes for a patient. Along with the development of tests based on the study of panels of oncologically significant genes or their regions, for various forms of genetically heterogeneous tumors a promising approach could be the use as an object of liquid biopsy of an individual spectrum of somatic mutations of a particular patient that can be detected on the basis of high-throughput sequencing of tumor tissue.Aim. To determine the applicability of different methods for detecting single-nucleotide somatic mutations detected in tumor tissue of a particular patient in cDNA preparations from blood plasma obtained before surgical removal of the tumor and to evaluate the possibility of quantifying the proportion of the alternative variant in the total pool of cDNA. Materials and methods. We used normal and tumor tissue, as well as blood plasma samples from patients with hepatocellular carcinoma, and various methods for detecting single-nucleotide somatic mutations: real-time polymerase chain reaction (PCR) with intercalating dye or with TaqMan probes, droplet digital PCR and high-throughput sequencing of target amplicons.Results. Using the example of a somatic mutation in the TLN1 gene detected in tumor tissue of a patient with hepatocellular carcinoma, methods were developed and tested, each of which allows specific detection of the mutant variant in small amounts (2 ng) of cDNA from the blood plasma of the same patient. The use of droplet PCR and target amplicon sequencing methods allowed us to quantify the proportion of the mutant variant in the total cDNA pool, which was 19.7 and 23.5 %, respectively.Conclusion. Among the methods investigated, droplet digital PCR and targeted amplicon sequencing allow not only reliable detection of mutant variants in small amounts of cDNA, but also adequate quantification, which is particularly important for the development of ways to monitor tumor growth during treatment. The close values of the proportion of mutant variants in cDNA detected by these methods indicate the accuracy of quantitative analysis and the possibility of their use for cross-validation of the results obtained.


  • Open Access

    Identification of a new methylation site in the Sept9 promoter region for the diagnosis of hepatocellular carcinoma

    by N. L. Lazarevich, P. M. Abramov, M. D. Fedorova, I. F. Kustova, D. A. Shavochkina, A. N. Katargin, N. P. Kisseljova, N. A. Dyakova, I. V. Botezatu, V. N. Kondratova, et al.

    Background. Over 600,000 people die from hepatocellular carcinoma (HCC) each year worldwide. The disease is often detected at advanced stages and in many cases is not curable. Early diagnostic and monitoring of HCC recurrences remains a substantial problem in clinical oncology. That determines the need for a search for highly sensitive and specific biomarkers for the non-invasive of HCC diagnostics. The objective of the study. Identification of the hypermethylated locus in the promoter region of the septin 9 (Sept9) gene based on the annotated methylomes from the public databases. Experimental validation of methylation on a pilot panel of paired clinical samples of patients with HCC, as well as tissue samples from patients with benign liver tumors and lymphocytes from healthy donors. Materials and methods. To analyze the methyl data, samples of HCC from TCGA, hepatocellular adenoma from GEO (Gene Expression Omnibus) depository, peripheral blood cells and tissues of healthy donors from Methbank were used. Experimental validation of methylation levels of the identified site was carried out on a pilot panel of clinical samples by bisulphite pyrosequencing using PyroMark Q24.Results. Based on the analysis of methylome data, we selected cg20275528 site, which is characterized by high level of methylation in HCC tissues and minimal levels of methylation in non-tumor liver tissue, hepatocellular adenoma and peripheral blood of healthy donors. Experimental testing on a pilot panel of clinical specimens showed that the level of marker site methylation in HCC (42 % median) is significantly higher than in non-tumor liver tissues (3 % median) and benign neoplasms (1.5 % median) and exceeds the threshold value in HCC compared to paired samples of adjacent non-tumor liver tissue in 20 out of 30 studied cases (66.6 %). The general possibility for cg20275528 methylation detection in circulating DNA of plasma in HCC patients was shown.Conclusion. The obtained results indicate that the approach to the detection and experimental verification of diagnostically significant markers developed and tested in this study can be used to identify new differentially methylated sites and to establish new approaches for non-invasive HCC diagnosis.


  • Open Access

    Potential of the use of methylation biomarkers for diagnostics and prognosis of hepatocellular carcinoma in liquid biopsy

    by I. F. Kustova, A. S. Makarova, N. L. Lazarevich

    Hepatocellular carcinoma (HCC) is one of the most common types of liver cancer that is mainly diagnosed at advanced stages. Since molecular markers that are currently used in clinical practice are not sensitive enough for effective diagnosis of HCC, active search of new biomarkers is underway. Usе of minimally invasive liquid biopsy allows to detect specific markers of tumor growth and particularly alterations of gene methylation patterns in cell-free DNA distinctive for HCC, in biological liquids of patients. In the present review the most promising diagnostic and prognostic methylation biomarkers that were detected in cell-free DNA of HCC patients are being considered.


    • 1 September 2010
      • Vol. 32  (3) , 167-71

    Deregulation of hepatocyte nuclear factor 4 (HNF4)as a marker of epithelial tumors progression.

    by N L Lazarevich, D A Shavochkina, D I Fleishman, I F Kustova, O V Morozova, E S Chuchuev, Y I Patyutko

    Tissue-specific transcription factors forming the regulatory cascades which determine the specification and differentiation of epithelial cells during embryogenesis, play the central role in the control of functional and morphological properties of different cell types. Hepatocyte nuclear factors (HNFs) network is one of the most investigated tissue-specific regulatory systems which controls the specification and maintenance of differentiation of several epithelial cell types. Nuclear receptor HNF4α is one of the central elements of this regulatory network in the liver. We have found that deregulation of this gene is associated with rodent and human hepatocellular carcinoma (HCC) progression and induces the increase of proliferation rate, loss of epithelial morphology, dedifferentiation and metastasis. Restoration of HNF4α expression in dedifferentiated cells induced partial reversion of highly malignant phenotype both in vitro and in vivo. In human HCC samples HNF4α transcription was completely lost or significantly decreased in about 70% of HCCs, not associated with hepatitis B virus infection. Decrease of HNF4α isoforms expression correlated with poor prognosis. Thus we propose HNF4α is a candidate tumor suppressor for hepatic cells. Dysfunction of different HNFs was also reported in other epithelial tumors. We suppose that tissue-specific transcription factors which control the key steps of definite differentiation programs and are capable to receive and modulate extracellular signals can be considered as promising tumor suppressor candidates for their corresponding tissues.


    • 23 June 1999
      • Vol. 33  (2) , 273-81

    [Expression of alpha-fetoprotein and hepatocyte nuclear factors in rat hepatoma clones: effect of retinoic acid].

    by E V Varga, I F Kustova, N L Lazarevich